Effective and safe

The Lancet published an article about the Sputnik Lite vaccine

Ekaterina Shutova, XX2 century

The Lancet published an article on the results of phase I—II clinical trials of the Sputnik Light vaccine (Tukhvatulin et al., An open, non-randomized, phase 1/2 trial on the safety, tolerance, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults).

During a study on 110 volunteers from St. Petersburg, Russian scientists from the Gamalea Center found out that the vaccine provides vaccinated with a good "humoral and cellular immune response" and does not entail serious side effects. The youngest participant in the clinical trials was 18 years old, the oldest was 59.

Before the start of the study, which took place in January 2021, scientists divided the volunteers into two groups — with antibodies to the SARS-CoV-2 coronavirus and without antibodies (the vast majority of participants — 96 people — had no antibodies). As a result, it turned out that vaccination with Sputnik Lite (recall that this one—component vaccine is an analogue of the first component of Sputnik V) provides an immune response to both the first and second. However, scientists note that on the 10th day after vaccination, the immune response was more pronounced in volunteers with antibodies.

"Interestingly, only volunteers without antibodies to SARS-CoV-2 complained of muscle and joint pain after vaccination," the authors write in the article (only 5 participants in clinical trials complained of pain). Side effects of moderate severity were found in 6 (5.5%) volunteers, but these side effects "turned out to be temporary." There were no serious consequences after vaccination.

According to scientists, the results of clinical trials prove that Sputnik Lite is excellent for revaccination. To date, the drug has been registered in more than 15 states.

Portal "Eternal youth" http://vechnayamolodost.ru